Fate Therapeutics, Inc. FATE
2.35
0.02
0.86%
as of 25 Sep
- Market cap
- $279.2M
- P/E
- 0.0×
Follow FATE
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(52.35%) | (51.84%) | (55.50%) | (60.75%) | |
| (37.23%) | (35.89%) | (38.01%) | (39.89%) | ||
ROIC |
(585.78%) | (2,617.38%) | (1,783.83%) | 0.00% | |
Return on Tangible Assets |
(61.79%) | (59.38%) | (63.96%) | (71.22%) | |
Average Days of Receivables |
34.88 | 50.31 | 40.68 | 39.53 | |
Free Cash Flow per Share |
(0.97) | (0.94) | (0.90) | (0.88) | |
Free Cash Flow |
(115.30) | (111.67) | (107.73) | (105.42) | |
Capital Expenditures |
(4.73) | (5.59) | (4.63) | (3.47) | |
Piotroski F-Score |
1.00 | 2.00 | 1.00 | 2.00 | |
| Other line items | |||||
Cash ROIC |
(24.60%) | (25.82%) | (29.08%) | (33.18%) | |
Accounts Receivable Turnover |
2.97 | 2.98 | 4.06 | 6.19 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,625.51% | 1,622.46% | 1,637.05% | 1,546.03% | |
Selling, General and Administrative Expense of Revenue |
716.24% | 699.98% | 670.42% | 612.05% | |
Share Based Compensation of Revenue |
399.55% | 375.02% | 339.96% | 274.78% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.71 | 0.78 | 0.79 | 0.81 | |
Depreciation/Fixed assets |
0.17 | 0.16 | 0.17 | 0.17 | |
Capex/Depreciation |
(0.46) | (0.60) | (0.50) | (0.40) | |
Revenue per Share |
0.06 | 0.06 | 0.05 | 0.05 | |
Operating CF per Share |
(0.93) | (0.89) | (0.86) | (0.85) | |
Capex per Share |
(0.04) | (0.05) | (0.04) | (0.03) | |
Capex to Sales |
0.66 | 0.84 | 0.73 | 0.54 | |
Net Profit Margin |
(2,187.11%) | (2,051.08%) | (2,056.79%) | (1,941.09%) |
Columns are period end dates